Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians

British Journal of Clinical Pharmacology

Volumn 81, Issue 6, 2016, Pages 1078-1090

  Hasunuma, Tomoko ^a,b   Tohkin, Masahiro ^c,d   Kaniwa, Nahoko ^d   Jang, In Jin ^e   Yimin, Cui ^f   Kaneko, Masaru ^g   Saito, Yoshiro ^d   Takeuchi, Masahiro ^b   Watanabe, Hiroshi ^h   Yamazoe, Yasushi ⁱ   Uyama, Yoshiaki ^j   Kawai, Shinichi ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c NAGOYA CITY UNIVERSITY   (Japan)

^d NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^e Seoul National University College of Medicine   (South Korea)

^f PEKING UNIVERSITY FIRST HOSPITAL   (China)

^g SNBL Clinical Pharmacology Center   (United States)

^h HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ TOHOKU UNIVERSITY   (Japan)

^j PHARMACEUTICALS AND MEDICAL DEVICES AGENCY   (Japan)

more..

Author keywords

Asian; difference; ethnic; extrinsic; intrinsic; pharmacokinetics

Indexed keywords

CYTOCHROME P450 2C9; GLUCURONOSYLTRANSFERASE 1A1; HEMOGLOBIN; INTRINSIC FACTOR; MELOXICAM; MOXIFLOXACIN; SIMVASTATIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; URIC ACID; GLUCURONOSYLTRANSFERASE; QUINOLONE DERIVATIVE; SLCO1B1 PROTEIN, HUMAN; THIAZINE DERIVATIVE; THIAZOLE DERIVATIVE; UGT1A1 ENZYME;

ADULT; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CHINESE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG URINE LEVEL; EAST ASIAN; ELIMINATION HALF-LIFE; ETHNIC DIFFERENCE; GENE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; JAPANESE (PEOPLE); KOREAN (PEOPLE); MACULOPAPULAR RASH; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; RASH; RENAL CLEARANCE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN PRURITUS; TIME TO MAXIMUM PLASMA CONCENTRATION; URIC ACID BLOOD LEVEL; URTICARIA; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CLINICAL TRIAL; GENETICS; MULTICENTER STUDY; URINE; YOUNG ADULT;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2C9; EUROPEAN CONTINENTAL ANCESTRY GROUP; FLUOROQUINOLONES; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; POLYMORPHISM, GENETIC; SIMVASTATIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY MEMBER 1B1; THIAZINES; THIAZOLES; YOUNG ADULT;

EID: 84960930483     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12884     Document Type: Article

References (45)

1. Fukunaga S, Kusama M, Arnold FL, Ono S,. Ethnic differences in pharmacokinetics in new drug applications and approved doses in Japan. J Clin Pharmacol 2011; 51: 1237-40.
2. Ichimaru K, Toyoshima S, Uyama Y,. Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors. Clin Pharmacol Ther 2010; 87: 362-6.
3. Yasuda SU, Zhang L, Huang SM,. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 2008; 84: 417-23.
4. Ling WH, Lee SC,. Inter-ethnic differences-how important is it in cancer treatment? Ann Acad Med Singapore 2011; 40: 356-61.
5. International Conference on Harmonisation; guidance on ethnic factors in the acceptability of foreign clinical data; availability-FDA. Notice. Fed Regist 1998; 63: 31790-6.
6. Kurose K, Sugiyama E, Saito Y,. Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet 2012; 27: 9-54.
7. Man M, Farmen M, Dumaual C, Teng CH, Moser B, Irie S, Noh GJ, Njau R, Close S, Wise S, Hockett R,. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol 2010; 50: 929-40.
8. Myrand SP, Sekiguchi K, Man MZ, Lin X, Tzeng R-Y, Teng C-H, Hee B, Garrett M, Kikkawa H, Lin C-Y, Eddy SM, Dostalik J, Mount J, Azuma J, Fujio Y, Jang I-J, Shin S-G, Bleavins MR, Williams JA, Paulauskis JD, Wilner KD,. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther 2008; 84: 347-61.
9. Kirchheiner J, Brockmoller J,. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005; 77: 1-16.
10. Goldstein JA,. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52: 349-55.
11. Klotz U, Schwab M, Treiber G,. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol 2004; 95: 2-8.
12. Ingelman-Sundberg M, Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005; 5: 6-13.
13. Ozawa S, Soyama A, Saeki M, Fukushima-Uesaka H, Itoda M, Koyano S, Sai K, Ohno Y,. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet 2004; 19: 83-95.
14. von Homeyer P, Schwinn DA,. Pharmacogenomics of beta-adrenergic receptor physiology and response to beta-blockade. Anesth Analg 2011; 113: 1305-18.
15. Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Saito T, Parkinson A, Nakagawa K, Kamataki T,. Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers. Xenobiotica 2005; 35: 69-83.
16. Komoto C, Nakamura T, Sakaeda T, Kroetz DL, Yamada T, Omatsu H, Koyama T, Okamura N, Miki I, Tamura T, Aoyama N, Kasuga M,. MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug Metab Pharmacokinet 2006; 21: 126-32.
17. Liu Z-Q, Liu J, Xiang ZH, Hu M-Y, Mo W, Wang L-S, Ou-Yang DS, He N, Wang D, Zhou H-H,. Distributive characteristics of Ser49Gly and Gly389Arg genetic polymorphisms of beta1-adrenoceptor in Chinese Han and Dai populations. Acta Pharmacol Sin 2006; 27: 254-8.
18. Perera V, Gross AS, McLachlan AJ,. Influence of environmental and genetic factors on CYP1A2 activity in individuals of South Asian and European ancestry. Clin Pharmacol Ther 2012; 92: 511-9.
19. Oishi M, Chiba K, Malhotra B, Suwa T,. Pharmacokinetics of tolterodine in Japanese and Koreans: physiological and stochastic assessment of ethnic differences. Drug Metab Pharmacokinet 2011; 26: 236-41.
20. Xia D-Y, Wang Y-H, Guo T, Li XL, Su XY, Zhao LS,. Pharmacokinetics of tramadol in a diverse healthy Chinese population. J Clin Pharm Ther 2012; 37: 599-603.
21. Yuen E, Gueorguieva I, Wise S, Soon D, Aarons L,. Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin. J Pharmacokinet Pharmacodyn 2010; 37: 3-24.
22. Yang L, Guo T, Sia D-Y, Zhao L-S,. Pharmacokinetics of losartan and its active carboxylic acid metabolite E-3174 in five ethnic populations of China. J Clin Pharm Ther 2012; 37: 226-31.
23. Guo T, Mao G-F, Xia D-Y, Su X-Y, Zhao L-S,. Pharmacokinetics of midazolam tablet in different Chinese ethnic groups. J Clin Pharm Ther 2011; 36: 406-11.
24. Lettieri J, Vargas R, Agarwal V, Liu P,. Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400 mg in healthy male volunteers. Clin Pharmacokinet 2001; 40: 19-25.
25. Mason JW, Florian JA, Garnett CE, Moon TE, Selness DS, Spaulding RR,. Pharmacokinetics and pharmacodynamics of three moxifloxacin dosage forms: implications for blinding in active-controlled cardiac repolarization studies. J Clin Pharmacol 2010; 50: 1249-59.
26. Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, Shirao K, Yamada Y, Ohmatsu H, Kubota K, Yoshida T, Ohtsu A, Saijo N,. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1 6 and 28. Pharmacogenet Genomics 2007; 17: 497-504.
27. Raju B, Ramesh M, Borkar RM, Srinivas R, Padiya R, Banerjee SK,. In vivo metabolic investigation of moxifloxacin using liquid chromatography/electrospray ionization tandem mass spectrometry in combination with online hydrogen/deuterium exchange experiments. Rapid Commun Mass Spectrom 2012; 26: 1817-31.
28. Tachibana M, Tanaka M, Masubuchi Y, Horie T,. Acyl glucuronidation of fluoroquinolone antibiotics by the UDP-glucuronosyltransferase 1 a subfamily in human liver microsomes. Drug Metab Dispos 2005; 33: 803-11.
29. Hiratsuka M, Sasaki T, Mizugaki M,. Genetic testing of pharmacogenetics and its clinical application in drug therapy. Clin Chim Acta 2006; 363: 177-86.
30. Zhang J, Rodila R, Gage E, Hautman M, Fan L, King LL, Wu H, El-Shourbagy TA,. High-throughput salting-out assisted liquid/liquid extraction with acetonitrile for the simultaneous determination of simvastatin and simvastatin acid in human plasma with liquid chromatography. Anal Chim Acta 2010; 28: 167-72.
31. Yuan Y, Chen X, Zhong D,. Determination of meloxicam in human plasma by liquid chromatography-tandem mass spectrometry following transdermal administration. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 852: 650-4.
32. Bae JW, Kim MJ, Jang CG, Lee SY,. Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 859: 69-73.
33. Azuma J, Ihara Y, Yoshida H, Nagakura A, Tarui S, Asakura M, Matsumura R, Kouhei H,. Phase I study of UHAC62 (meloxicam). Clin Rep 1996; 30: 3189-210.
34. Sullivan JT, Woodruff M, Lettieri J, Agarwal V, Krol GJ, Leese PT, Watson S, Heller AH,. Pharmacokinetics of a once-daily oral dose of moxifloxacin (bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob Agents Chemother 1999; 43: 2793-7.
35. Tanaka T, Yoshikawa K, Orii Y, Tsuboi T, Kawano K, Stass H, Tateisi T,. Interethnic difference in the pharmacokinetics of a novel quinolone antibiotic, BAY 12-8039 (moxifloxiacin) and estimation of its clinical dose. Jpn J Clin Pharmacol Ther 1999; 30: 231-2.
36. Moise PA, Birmingham MC, Schentag JJ,. Pharmacokinetics and metabolism of moxifloxacin. Drugs Today 2000; 36: 229-44.
37. Suresh D, Srinivasan K,. Influence of curcumin, capsaicin, and piperin on the rat liver drug-metabolizing enzyme system in vivo and in vitro. Can J Physiol Pharmacol 2006; 84: 1259-65.
38. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, Schneck D,. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005; 78: 330-41.
39. Ieiri I, Higuchi S, Sugiyama Y,. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol 2009; 5: 703-29.
40. Tirona RG,. Ethnic differences in statin disposition. Clin Pharmacol Ther 2005; 78: 311-6.
41. Vesell ES, Penno MB,. Assessment of methods to identify sources of interindividual pharmacokinetic variations. Clin Pharmacokinet 1983; 8: 378-409.
42. Karlsson MO, Sheiner LB,. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 1993; 21: 735-47.
43. Kaniwa N, Aoyagi N, Ogata H, Ejima A,. Gastric emptying rates of drug preparations. I. Effects of size of dosage forms, food and species on gastric emptying rates. J Pharmacobiodyn 1988; 11: 563-70.
44. Jáuregui-Garrido B, Jáuregui-Lobera I,. Interactions between antihypertensive drugs and food. Nutr Hosp 2012; 27: 1866-75.
45. Schwartz JB,. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther 2007; 82: 87-96.